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In response to DNA damage, TLS (translesion synthesis) allows replicative bypass of 
various DNA lesions, which stall normal replication. TLS is achieved by low-fidelity 
polymerases harboring less stringent active sites. In human, Y-family polymerases 
together with Pol ζ (polymerase ζ) are responsible for TLS across different types of 
damage. Protein-protein interaction contributes significantly to the regulation of TLS. 
REV1 plays a central role in TLS because it interacts with all other Y-family members 
and Pol ζ. Ubiquitin-dependent regulatory mechanisms also play important roles in 
TLS. Ubiquitin binding domains have been found in TLS polymerases and they might 
be required for TLS activity. Monoubiquitination of PCNA (proliferating cell nuclear 
antigen), the central scaffold of TLS polymerases, is thought to promote TLS. In 
addition, both non-proteolytic and proteolytic polyubiquitination of PCNA and TLS 
polymerases has been demonstrated. Owing to their low fidelity, the recruitment of 














Transmission of genetic materials from one generation to the next is the essence of 
life. Organisms have evolved accurate machineries to ensure faithful replication of 
DNA genome. Replicative DNA polymerases are characteristic for their high 
processivity and high fidelity which are achieved by their stringent active sites and the 
3′-5′ proofreading exonuclease activity. DNA, however, is constantly subject to 
damage caused by both extrinsic and intrinsic agents, such as UV light and reactive 
oxygen species. In order to maintain the integrity of genome, cells are endowed with 
elaborate DNA damage repair mechanisms, including nucleotide excision repair, base 
excision repair, mismatch repair, homologous recombination and non-homologous 
end joining, to remove DNA lesions before replication starts. However, some 
damages may escape from the repair machinery and persist in the genome. Such 
lesions on DNA template hinder the incorporation of nucleotides by replicative DNA 
polymerases because the stringent active sites of these polymerases accommodate 
normal template bases and correct complementary nucleotides only. Consequently, 
unrepaired DNA lesions cause replication block. Since stalled replication forks can 
lead to major chromosome abnormalities and cell death, replicative arrests have to be 
circumvented to maintain cell survival. Cells have evolved DNA damage tolerance or 
post-replicative repair mechanisms to bypass damages, restoring DNA replication. 
One proposed lesion bypass pathway involves template switching in which the 
undamaged sister chromatid, instead of the damaged strand is used as a template for 
DNA replication in order to restore the correct sequence opposite the lesion. This 
pathway is generally considered to be error-free and the proposed models are 
discussed in a recent review [1].  
Another DNA damage tolerance pathway which is extensively studied is TLS 
(translesion synthesis), in which nucleotides are inserted opposite the lesion, without 
repairing it. TLS employs specialized DNA polymerases which lack proofreading 
activity and have low processivity as well as low fidelity. In contrast to replicative 
polymerases, their active sites are more relaxed and thus can accommodate bulky 
distorted damaged bases [2]. TLS is evolutionarily conserved and the proteins 
involved can be found in bacteria and in both lower and higher eukaryotes. Most of 
these proteins belong to Y-family of DNA polymerases, a new family following five 
preceding ones (A, B, C, D and X). In bacteria there are DNA Pol (polymerase) IV 
and Pol V. In budding yeast, there are two members, REV1 and Pol η. In mammals, 
Y-family polymerases expand to four members, REV1, Pol η, Pol ι and Pol κ, 
implicating the complexity of TLS in higher eukaryotes [3]. In addition to Y-family 
polymerases in eukaryotes, Pol ζ is a member of the B-family DNA polymerases, 
which include high-fidelity replicative polymerases such as Pols α, δ and ε, yet 
displays TLS activity. Pol ζ is capable of extending terminally mismatched or 
distorted primers opposite to DNA lesions more efficiently than Pol α. Like Y-family 
polymerases, Pol ζ has low processivity [4] and does not possess 3′-5′ proofreading 
exonuclease activity [5].  
 
Mammalian translesion polymerases 
Like high-fidelity replicative polymerases, Y-family DNA polymerases contain the 
typical catalytic core, including thumb, fingers and palm domains, in the central 
region of the proteins. Structural studies of TLS DNA polymerases, however, reveal 
that the thumb and finger domains are remarkably shorter than those in replicative 
DNA polymerases. This structure gives a more open and relaxed active site to 
accommodate bulky DNA lesions and to allow mismatched base pairing to occur. 
Such loose conformation generates a considerably smaller interface between the DNA 
buries and the catalytic core. Consequently, the “induced-fit” conformational change 
around the active site is apparently destroyed, conferring low fidelity on Y-family 
polymerases [6]. In addition to the catalytic core, Y-family DNA polymerases also 
harbor a little finger domain, also referred as PAD (polymerase-associated domain), at 
the C terminus of the catalytic core. PAD extends from the fingers domain to mediate 
DNA binding and the movement of primer-template duplex [2]. The interaction 
between PAD and the primer-template duplex after nucleotide insertion opposite the 
damaged base is proposed to trigger polymerase switch, likely through 
conformational change [7]. Although the amino acid sequence of PAD is relatively 
diverse among the members of Y-family polymerases, its structural conformation is 
conserved. Noticeably, the diversity of PAD sequence may contribute to the 
differences in lesion specificity among the members in the family [2].  
In general, TLS is considered to be a mutagenic process owing to the low fidelity 
of polymerases involved. However, some TLS polymerases are capable of replicating 
over certain lesions efficiently and with considerable accuracy; one prominent 
error-free example of TLS is carried out by Pol η. Pol η is exclusively found in 
eukaryotes and it is particularly important to human because of its protective role 
against skin cancer. Loss of Pol η activity is identified in a genetic disorder known as 
XPV (xeroderma pigmentosum variant), which is more vulnerable to skin cancer and 
has higher sensitivity to sunlight [8]. Pol η is able to accurately and efficiently 
replicate through CPDs (cyclobutane pyrimidine dimers), a major UV-induced DNA 
lesion [9]. Elevated UV-induced mutation frequency is observed in Pol η knockout 
mouse embryonic fibroblasts [10]. On the other hand, overexpression of Pol η does 
not increase spontaneous mutation in human cells [11]. It is apparent that Pol η is 
specialized for the bypass of CPD in an error-free manner, and this accurate process is 
less likely to be substituted by other polymerases in the family. In support of this, 
human Pol η has low processivity with undamaged DNA whereas the processivity 
increases remarkably when it bypasses cis-syn thymine dimer, and it preferentially 
inserts dATP opposite both thymines [7]. In primary fibroblasts of Pol η knockout 
mice, UV-induced mutagenesis is largely suppressed by depletion of Pol ι [12]. It 
implies that individual mammalian TLS polymerase may target specific lesions 
induced by various DNA damaging agents.   
In spite of the conservation of polymerase catalytic core, REV1 is a dCMP 
transferase with restricted activity in inserting dCMP not only opposite template G but 
also opposite other template bases [13]. At the N terminus of REV1, there is a BRCT 
(BRCA1 C-terminal) domain, which is unique among Y-family members. BRCT 
domain is required for REV1 to bind PCNA (proliferating cell nuclear antigen). 
Deletion or inactivation of BRCT domain abrogates the localization of REV1 to 
replication foci in nucleus. BRCT domain is also required for cell survival and DNA 
damage-induced mutagenesis in yeast and chicken DT40 cells [3]. Notably, BRCT 
domain and dCMP transferase activity of human REV1 are not required for effective 
DNA damage tolerance [14]. It is therefore obvious that BRCT domain provides 
another layer of regulation for REV1, which is absent from other members of 
Y-family polymerases.  
REV1 plays a pivotal role in maintaining genomic integrity by TLS and it works 
closely with Pol ζ for most spontaneous and induced mutagenesis in yeast [3]. REV1 
physically binds to many proteins in the TLS pathway. The C-terminal 100-150 amino 
acids of mammalian REV1 can interact with other Y-family polymerases including 
Pols η, κ and ι (Figure 1), whilst PAD of REV1 binds Pol η in yeast [15]. The 
sequence homology in the C-terminal region of REV1 is more conserved among 
higher vertebrates (such as human and mouse) than among lower eukaryotes (for 
example, fungi and yeast) [16]. This may explain the variation of binding targets 
between human and yeast REV1 orthologues. Very recently a novel RIR 
(REV1-interacting region) has been identified in the C-terminal region of human Pols 
κ, ι, and η. Pol κ mutant deficient in RIR is unable to restore UV resistance of Pol κ 
null cells [17]. BRCT domain, PAD as well as the C-terminal region of yeast REV1 
are capable of physically interacting with REV7, the accessory subunit of Pol ζ [18]. 
Besides binding to REV7 [19], the C-terminus of yeast REV1 can also bind to REV3, 
the catalytic subunit of Pol ζ, and this interaction promotes the proficiency of Pol ζ 
for mismatch extension and extension opposite DNA lesions [20]. Interaction between 
REV1 and REV7 is conserved in all organisms including yeast, mouse and human, 
implicating the important role of REV1 in TLS by Pol ζ. It is noteworthy that dCMP 
transferase activity of yeast REV1 is not required for UV mutagenesis because dCMP 
is rarely inserted opposite UV-induced lesions [21]. Further, the transferase activity of 
REV1 is dispensable for the bypass of abasic sites [22] and lesion modified by 
N-2-acetylaminofluorene [23]. Both yeast wild-type REV1 and its polymerase- 
deficient mutant are capable of interacting with REV3 and REV7 independently and 
these complexes are localized to DNA lesions [24]. Taken together, REV1 likely 
serves a structural role in TLS by Pol ζ. 
Pol ζ is a heterodimeric complex comprising REV3 and REV7. Upon binding to 
REV7, the catalytic activity of REV3 is enhanced [4]. Like REV1, Pol ζ is a TLS 
enzyme conserved in eukaryotes, from yeast to human. Nevertheless, polymerase 
activity has not been demonstrated in mammalian Pol ζ, in contrast to its yeast and 
Drosophila counterparts [4, 25]. Both REV3 and REV7 belong to B-family of DNA 
polymerases, and Pol ζ possesses a relatively higher fidelity than Y-family 
polymerases though REV3 is devoid of 3′-5′ proofreading exonuclease activity [4]. 
Whilst Pol ζ is not efficient in replicating through DNA lesions, it is competent to 
extend from mispaired primer termini. Therefore, the primary role of Pol ζ in TLS is 
proposed to extend from the nucleotides inserted opposite the lesion by other TLS 
enzyme(s) [3]. One example is that human Pol ι and Pol ζ cooperate sequentially in a 
way that the former inserts nucleotides opposite damage sites and the latter acts as an 
primer extension enzyme [26]. We have demonstrated that suppression of human 
REV7 in cultured cancer cells using RNAi (RNA interference) technique results in 
hypersensitivity to DNA-damaging agents, impaired sister chromatid exchange, 
reduction in frequencies of spontaneous and drug-induced mutations, and increase in 
chromosome aberration in response to DNA damage [27]. These findings agree with 
the observations in avian cells, implicating the evolutionarily conserved role of REV7 
in DNA damage pathway in eukaryotes. Reduction of REV3 expression in yeast 
substantially decreases UV-induced mutation frequency [5] and disruption of REV3 
gene in mice is embryonic lethal. Mouse cells with REV3 gene interrupted have lower 
survival rate and more cells arrested in S or G2/M phase of cell cycle [28]. Chicken 
DT40 cells with homologous deletion of REV3 are sensitive to DNA-damaging agents 
and cells are accumulated in G2 phase [29]. These data suggest that the functional role 
of REV3 in TLS is conserved among species. In yeast, REV3-deleted cells arrest in 
G2 upon UV irradiation [30]. Intriguingly, yeast REV1 is expressed in a cell 
cycle-dependent manner, in which REV1 mRNA and protein levels peak at G2/M 
phase and this expression profile does not alter drastically after DNA damage by UV 
[2]. Given the indispensability of REV1 in TLS by Pol ζ, yeast and mammalian 
models suggest that REV3 functions after S phase, conceivably in G2/M, and this 
coincides with the expression pattern of REV1, highlighting the tight functional 
relationship between these two TLS proteins.  
Apart from its role in TLS, REV7 has another identity in cell cycle regulation. 
Human REV7 is also called MAD2B, MAD2L2 or MAD2β for its high sequence 
homology with a mitotic checkpoint protein MAD2 [31, 32]. Like MAD2, MAD2B is 
able to bind CDH1 and/or CDC20, activators of APC (anaphase promoting complex), 
thereby inhibiting APC activation. Although MAD2B is homologous to MAD2, it 
does not bind to MAD1, an anchoring protein for MAD2 at the kinetochore at the 
onset of mitotic checkpoint, suggesting that MAD2B may deliver signal other than 
mitotic checkpoint activation to APC-mediated proteolytic pathway [31, 32]. The role 
of MAD2B in mitotic checkpoint is also demonstrated in the infection process of 
intestinal epithelial cells by Shigella. IpaB, an effector protein in Shigella for bacterial 
invasion of host cells, interacts with MAD2B in G2/M phase, leading to unscheduled 
activation of APCCdh1 and subsequent degradation of APC substrates such as cyclin B 
and CDC20, which in turn elicits G2/M arrest [33]. The novel role of REV7 in mitotic 
checkpoint, which in particular is associated with APC-mediated proteolysis, hints 
that REV7 may act as a mediator to link between ubiquitin-mediated proteolysis and 
DNA damage pathways [34]. Identification of REV7 targets for protein degradation 
therefore can provide evidence to support the crosstalk between these two important 
pathways in cells (Figure 1).  
 
Role of ubiquitin in translesion synthesis 
In order to implement TLS, the access and recruitment of TLS proteins to a damaged 
site are prerequisites. Eukaryotic PCNA is a homotrimeric protein which constitutes a 
donut-shaped structure surrounding double-stranded DNA. It slides along DNA 
during replication, providing a platform to tether the replicative polymerases to the 
DNA template. Since replication fork is stalled at DNA lesions, it is perceived that 
PCNA also serves as a docking site for TLS proteins. Indeed all eukaryotic Y-family 
polymerases, except REV1, contain PIP (PCNA interacting peptide) which allows 
them to interact with PCNA while the binding with PCNA requires BRCT domain of 
REV1 [3]. REV1 protein localizes to the nucleus exclusively and colocalizes with 
PCNA in replication foci, the replication machineries in S-phase cells, only when 
BRCT domain is intact. Considering that Y-family polymerases can associate with 
PCNA and mammalian REV1 is able to interact with other members in the Y-family 
and Pol ζ (Figure 1), it is prone to speculate that TLS polymerases display high 
avidity toward PCNA, like replicative polymerases. In fact the recruitment of TLS 
polymerases is regulated rigidly through posttranslational modification of PCNA by 
ubiquitin. “Polymerase switch” is a generally accepted model in which PCNA acts as 
a platform where replicative polymerases are switched to TLS polymerases to carry 
out lesion bypass [35]. In response to DNA damage, a replication fork is stalled at a 
lesion where single-stranded DNA is generated and this triggers the activation of an 
E3 ubiquitin ligase RAD18. RAD18 together with an E2 ubiquitin-conjugating 
enzyme RAD6 forms an E2-E3 complex which monoubiquitinates PCNA at K164. 
Meanwhile USP1 (ubiquitin specific protease 1), a deubiquitinase, is degraded by an 
autocleavage mechanism to prevent the removal of ubiquitin from PCNA [36]. The 
activation of ubiquitin ligase and inactivation of deubiquitinase deliberately promote 
the formation of monoubiquitinated PCNA persistently, which consequently promotes 
TLS [37]. Although PCNA is thought to be monoubiquitinated only when it is loaded 
at stalled replication fork, PCNA monoubiquitination is dispensable for fork 
progression on damaged DNA, but required for post-replicative gap filling [38]. 
Noticeably, monoubiquitinated PCNA particularly activates Pol η and REV1, 
concurring with a role in promoting TLS [35]. In addition, PCNA is 
monoubiquitinated in a RAD18-dependent manner upon UV irradiation of human 
cells, and Pol η only interacts with monoubiquitinated PCNA, but not unmodified one 
[39]. PCNA monoubiquitination is also required for Pol η-dependent error-free 
incorporation of dCMP opposite 8-oxoguanine [40]. 
UBM (ubiquitin binding motif) and UBZ (ubiquitin-binding zinc finger) domains 
have been found in TLS polymerases [41]. These domains are evolutionarily 
conserved in all Y-family polymerases and are located at the C-terminal region of the 
proteins [3]. With possible exceptions [42], UBM and UBZ are generally required for 
polymerases to bind ubiquitin and to localize to replication foci [43, 44]. In particular, 
they promote robust interaction between TLS polymerases and monoubiquitinated 
PCNA [45, 46]. In the absence of DNA damage, monoubiquitination of PCNA is 
inhibited by deubiquitinase USP1, thereby prohibiting the switch from replicative to 
TLS polymerases. The timely monoubiquitination of PCNA during DNA damage 
therefore confers a spatial and temporal regulation on recruitment of TLS proteins to 
bypass lesions. Structural analysis reveals that PIP of Pol η interacts with PCNA 
stronger than UBM does [47]. The relative affinity between different PCNA binding 
motifs hence could limit the binding of Pol η to monoubiquitinated PCNA, rather than 
other ubiquitinated products induced by DNA damage. Since all three monomers of 
PCNA can be monoubiquitinated simultaneously and monoubiquitinated PCNA does 
not alter the activity of replicative DNA polymerase, it is possible that replicative 
DNA polymerases may not be displaced from PCNA during TLS at lesion sites [42]. 
On the other hand, each monoubiquitinated monomer may bind to different TLS 
polymerase which attempts to access the stalled primer terminus on a trial and error 
basis [3]. However, the exact mechanism of polymerase switching remains to be 
elucidated.  
The massive interactions among the members of TLS polymerases, and between 
these members and PCNA via ubiquitin, together with distinct efficacies of TLS 
polymerases toward various lesions, impose the idea of a two-step model in which 
two polymerases are involved in TLS. For example, Pol η binds to and targets Pol ι to 
replication foci [48]. Pol ζ is not efficient in inserting nucleotides opposite DNA 
lesions while it efficiently extends from nucleotides. It thus cooperates with other 
polymerases for incorporating nucleotide to achieve TLS [22, 26, 49] and various 
combinations of the two polymerases also determine the activation of either error-free 
or error-prone pathways [49]. 
It is not surprising that PCNA and TLS polymerases can also be regulated by 
polyubiquitination. Modification of PCNA at lysine 164 with lysine 63-linked 
polyubiquitin chain by yeast RAD5 and mammalian HLTF (helicase-like transcription 
factor)/SHPRH (SNF2 histone linker PHD ring helicase) does not cause proteolysis, 
but prevents TLS by promoting error-free damage avoidance [50-52]. On the other 
hand, polyubiquitination-dependent proteasomal degradation of yeast Pol η has been 
demonstrated [53]. This raises the interesting question as to whether the stability of 
other TLS polymerases might also be regulated by polyubiquitination and degradation. 
Particularly, because REV7 interacts with REV1 and REV3 [19] on one hand, and 
regulates APCCDH1 or APCCDC20 on the other hand, it will be of great interest to 
investigate whether REV1 and REV3 might undergo APC-dependent proteolysis 
through their interaction with REV7 (Figure 1). Plausibly, polyubiquitination of 
PCNA and TLS polymerases both associated and not associated with 












TLS is an important DNA damage tolerance pathway and it employs low fidelity 
polymerases to replicate across lesions, which arrest replication by replicative 
polymerases. Identification of different binding domains, such as RIR for REV1 
binding, and PIP plus UBM for PCNA binding, in TLS polymerases enables us to 
comprehend the functional relationship among these proteins. TLS polymerases have 
low fidelity, introducing mutations in the genome. Therefore, strict control of TLS 
polymerases is essential. Ubiquitin-dependent regulation of TLS polymerases is 
known to execute at different levels. Monoubiquitination of scaffold protein PCNA 
and its subsequent interaction with TLS polymerases are a key regulatory step that 
recruits TLS polymerases to the lesions. However, further investigations are required 
to elucidate the detailed mechanism of polymerase switching. Yeast REV1 protein is 
expressed in a cell cycle-dependent manner in which the level peaks at G2/M phase. 
Yeast Pol η has fast protein turnover, which is regulated by proteosome-mediated 
degradation. It remains elusive whether expression levels of other TLS polymerases in 
yeast and human are regulated in response to DNA damage. Posttranslational 
modification of proteins, such as ubiquitination and phosphorylation, can modulate 
protein stability, localization, activity, protein interaction, and direct the target 
proteins to different signaling pathways. Hence, a comprehensive repertoire of TLS 
protein modifications would lend us insights into the regulation of and the 
interrelation of the components in TLS. Pol ζ is a key protein in TLS and its subunit 
REV7 is also participating in mitotic checkpoint in which it inhibits APC-proteasome 
pathway. If TLS polymerases are able to be covalently linked to ubiquitin, they can be 
our targets of study to investigate whether there is a crosstalk between DNA damage 
tolerance and ubiquitination machinery. 
Figure legend 
Figure 1 Multilayered interactions of mammalian REV1 between components in 
TLS and APC-mediated proteolysis.  
Mammalian Y-family polymerases consist of REV1, Pol κ, Pol ι and Pol η. REV1 
interacts with Pol κ, Pol ι and Pol η using its C-terminal 100-150 residues. Two 
UBMs (UBM1 and UBM2) of REV1 are required for the association with PCNA 
which is monoubiquitinated at lysine 164 (K164) during DNA damage. Similarly, 
ubiquitin binding domains at the C-termini of other Y-family polymerases (UBZ of 
Pol κ and Pol η, and UBM of Pol ι) are able to interact with monoubiquitinated 
PCNA. PCNA is a homotrimer and it is plausible that all subunits may be 
monoubiquitinated, thus interacting with three proteins at the same time. All Y-family 
polymerases, except REV1, possess PIP which can bind PCNA regardless of the 
ubiquitination state of PCNA. Although REV1 lacks PIP, BRCT domain at the 
N-terminus of REV1 is responsible for interacting with PCNA. REV7, the accessory 
subunit of Pol ζ, interacts with the catalytic subunit REV3 and promotes its activity. 
REV7 binds to the C-terminal region of REV1 without affecting its activity. REV7 
can interact with the activator of APC, CDH1 and/or CDC20, thereby inhibiting the 
activation of APC. APC is an E3 ubiquitin ligase which covalently conjugates 
ubiquitin moiety to target substrates subject to proteasomal degradation. 
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